Trials / Completed
CompletedNCT01536366
Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide
Effect of BIA 9-1067 on the Pharmacokinetics of Repaglinide in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Bial - Portela C S.A. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the CYP2C8 inhibition by BIA 9-1067.
Detailed description
Single-centre, open-label, randomised, two-way crossover study in healthy young male and female volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIA 9-1067 | 25 mg BIA 9-1067 (single-dose) |
| DRUG | Repaglinide | 0.5 mg repaglinide (single-dose) |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2009-07-01
- Completion
- 2011-01-01
- First posted
- 2012-02-22
- Last updated
- 2015-08-20
- Results posted
- 2015-08-20
Locations
1 site across 1 country: Portugal
Source: ClinicalTrials.gov record NCT01536366. Inclusion in this directory is not an endorsement.